# The cannabis communication gap between cancer patients, providers: 5 notes > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-cannabis-communication-gap-between-cancer-patients-providers-5-notes/ > **Published:** 2026-07-23T17:14:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:32-04:00 > **Clinical Summary:** Cancer patients use cannabis without telling oncologists. Learn why communication matters, what interactions to monitor, and how to ask. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. CancerSafetyPainAnxietyResearchMental HealthDosing Why This Matters Cancer patients frequently use or consider cannabis for symptom management, but many do not disclose this to their oncology providers due to communication barriers, creating safety risks from potential drug interactions and unclear efficacy. Clinicians need structured conversations about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) to accurately assess medication interactions, provide evidence-based guidance on symptom management alternatives, and build trust that enables more comprehensive [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Addressing this communication gap is essential for optimizing cancer treatment outcomes and ensuring patients make informed decisions about complementary therapies. Clinical Summary Cancer patients and their healthcare providers often fail to communicate openly about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), creating a significant gap that may compromise patient safety and treatment optimization. This communication breakdown stems from multiple factors including provider discomfort with cannabis discussions, limited clinical evidence in oncology contexts, and patient concerns about judgment or legal consequences. The absence of transparent dialogue prevents clinicians from understanding patients’ [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns, potential drug interactions with chemotherapy or supportive medications, and unvalidated claims about symptom management that patients may be pursuing. Addressing this gap requires oncology teams to develop standardized protocols for discussing cannabis, educate themselves on current evidence regarding cannabinoids in cancer care, and create a non-judgmental clinical environment that encourages disclosure. Healthcare systems should consider integrating cannabis counseling into oncology staffing models and establishing clear guidelines for when to refer patients to specialists with expertise in [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). Clinicians should proactively ask all cancer patients about cannabis use and maintain evidence-based conversations to ensure comprehensive care coordination and protect patient safety. Clinical Perspective πŸ₯ The communication gap between cancer patients and their providers regarding [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use reflects a broader challenge in oncology practice: patients increasingly seek cannabis for symptom management and perceived therapeutic benefits, yet many clinicians lack sufficient training, confidence, or evidence-based guidance to engage in informed discussions. This gap is particularly concerning given that cancer patients may be using cannabis concurrently with conventional treatments without disclosing it to their care team, potentially creating [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) risks and complicating symptom assessment. The evidence base for cannabis in cancer care remains limited and heterogeneous, with most data restricted to cannabinoids for chemotherapy-induced nausea, [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/), and pain rather than direct antitumor effects, making nuanced counseling difficult. Healthcare providers should proactively initiate non-judgmental conversations about cannabis use as part of routine oncology history-taking, acknowledge the gap in current evidence, clarify what symptoms might reasonably be addressed through πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20cannabis%20communication%20gap%20between%20cancer%20patients%2C%20providers%3A%205%20notes%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71260)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71260)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20cannabis%20communication%20gap%20between%20cancer%20patients%2C%20providers%3A%205%20notes%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71260)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cancer survivors and providers differ in views on medical cannabis, study finds](https://cedclinic.com/cancer-survivors-and-providers-differ-in-views-on-medical-cannabis-study-finds/) - [Cancer survivors and providers differ in views on medical cannabis, study finds](https://cedclinic.com/cancer-survivors-and-providers-differ-in-views-on-medical-cannabis-study-finds/) - [Cancer survivors and providers differ in views on medical cannabis, study finds](https://cedclinic.com/cancer-survivors-and-providers-differ-in-views-on-medical-cannabis-study-finds/) πŸ“° Source: [https://www.beckersoncology.com/oncology/the-cannabis-communication-gap-between-cancer-patients-providers-5-notes/](https://www.beckersoncology.com/oncology/the-cannabis-communication-gap-between-cancer-patients-providers-5-notes/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).